# The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

> **NCT02380196** · — · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 100 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02380196
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02380196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02380196, "The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02380196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*